The new therapeutic strategy for Chronic Kidney Disease involving CD147/Basigin

涉及CD147/Basigin的慢性肾脏病新治疗策略

• 批准号: 23591188
• 负责人: KOSUGI TOMOKI
• 金额: $ 3.41万
• 依托单位: Nagoya University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591188/
• 关键词: CD147/Basigin; ループス腎炎; 糖尿病性腎症; CD1４７; ATP産生; Glucose代謝; インスリン抵抗性; Lupus腎炎; 補体C３活性; 抗dsDNA抗体; 免疫複合体; CD147; 補体C3活性; 抗ｄｓ－DNA抗体

CD147/Basigin, a glycosylated transmembrane protein, plays important roles of cell survival, invasion and metastasis. With regard to diabetes and autoimmune diseases, however, the molecular mechanisminvolving CD147 remains unknown. As CD147 identifies activated regulatory T cell (Treg), the attention has become extended to the autoimmune diseases. Interleukin (IL)-17 producing T cell and Treg also serve important roles in the pathogenesis of SLE. In the present study, lack of CD147 promotes Th17 differentiation through the STAT3 activation, eventually leading to the development of lupus nephritis. On the other hand, CD147 play deleterious effects in renal inflammation caused by ischemia and renal fibrosis through the enhanced infiltration of inflammatory cells. Diabetes is also influenced by CD147 in renal inflammation. Our results may shed light on the mechanisms underlying the pathogenesis of diabetes nephropathy and lupus nephritis.

CD 147/Basigin是一种糖基化的跨膜蛋白，在细胞的生存、侵袭和转移中起重要作用。然而，关于糖尿病和自身免疫性疾病，涉及CD 147的分子机制仍然未知。随着CD 147识别活化的调节性T细胞（Treg），注意力已经扩展到自身免疫性疾病。产生白细胞介素（IL）-17的T细胞和调节性T细胞在SLE的发病机制中也起重要作用。在本研究中，缺乏CD 147通过STAT 3激活促进Th 17分化，最终导致狼疮肾炎的发展。另一方面，CD 147通过促进炎症细胞浸润，在缺血性肾损伤和肾纤维化中发挥有害作用。糖尿病也受到肾脏炎症中CD 147的影响。本研究结果可能有助于阐明糖尿病肾病和狼疮性肾炎的发病机制。

项目成果

CD147/basigin reflects renal dysfunction in patients with acute kidney injury

• DOI: 10.1007/s10157-013-0916-3
• 发表时间: 2014-10-01
• 期刊: CLINICAL AND EXPERIMENTAL NEPHROLOGY
• 影响因子: 2.3
• 作者: Nagaya, Hiroshi;Kosugi, Tomoki;Maruyama, Shoichi
• 通讯作者: Maruyama, Shoichi

ミッドカイン（MK）がepoxyeicosatrienoic acids(EETs)を抑制し血圧制御に関与する

Midkine (MK) 抑制环氧二十碳三烯酸 (EET) 并参与血压控制

• 发表时间: 2013
• 作者: 佐藤 由香;佐藤 和一;増田 智広;小杉 智規;丸山 彰一;今井 圓裕;松尾 清一
• 通讯作者: 松尾 清一

A Comparison of the Acute Kidney Injury Network and Kidney Disease : Improving Global Outcomes Criteria for Acute Kidney Injury in Critically Ill Patients

急性肾损伤网络与肾脏疾病的比较：改善危重患者急性肾损伤的全球结局标准

• 发表时间: 2011
• 作者: Tanaka R;Sasaki-Ikesawa K;Shimura H;Nishioka K;Hattori N;Tanaka S;Kaji R.;Shinjo H
• 通讯作者: Shinjo H

The Pivotal Role of Midkine on the Development of Hypertension in Endothelial Dysfunction

中期因子在内皮功能障碍引起的高血压发展中的关键作用

• 发表时间: 2011
• 作者: Kuwabara T;Mori K;Mukoyama M;Kasahara M;Yokoi H;Saito Y;Ogawa Y;Imamaki H;Kawanishi T;Ishii A;Koga K;Mori KP;Kato Y;Sugawara A;Nakao K;Yuka Sato
• 通讯作者: Yuka Sato

The Growth Factor Midkine Ameliorates Crescentic Glomerulonephritis through Inhibiting Thrombosis

生长因子中期因子通过抑制血栓形成改善新月体肾小球肾炎

• 发表时间: 2011
• 作者: Johno H;Nakajima S,Kato H,Yao J;Paton AW;Paton JC;Katoh R;Shimizu F;and Kitamura M;Hibiki Shinjo;Hiroshi Kojima
• 通讯作者: Hiroshi Kojima